2013 ASH Poster Presentations

  • An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman’s Disease  Presenter: Frits van Rhee
  • Gene Expression Profiling-Based Risk Stratification Scores In Multiple Myeloma Can Be Highly Sensitive Towards Sample Preparation  Presenter: Qing Zhang
  • Non-Producing Multiple Myeloma (MM) Is a Distinct Subset Of Non-Secretory MM Characterized By High Cyclin D1 Expression and Decreased Progression Free Survival  Presenter: Xenofon Papanikolaou
  • Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL  Presenter: Christoph Heuck
  • Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma  Presenter: Christoph Heuck
  • Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma  Presenter: Christoph Heuck
  • GPRC5D Is a Cell Surface Plasma Cell Marker Whose Expression Is High In Myeloma Cells and Reduced Following Coculture With Osteoclasts  Presenter: Sathisha Upparahalli Venkateshaiah
  • Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis  Presenter: Tarun Garg
  • Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)  Presenter: Erming Tian
  • Healthy Donor Whole Bone Marrow Cells Preconditioned With Myeloma Patient Serum Support Long-Term Survival Of Primary Myeloma and Reveal Altered Microenvironmental Pathways  Presenter: Rakesh Bam
  • Intra-Tumoral Heterogeneity In Multiple Myeloma Gleaned From Gene Expression Profiling Analysis Of Plasma Cells and Bone Marrow Biopsies: Comparison Of Random Bone Marrow Samples and CT-Guided Fine Needle Aspirations Of MRI-Defined Focal Lesions  Presenter: Bart Barlogie
  • MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma  Presenter: Ya-Wei Qiang
  • Inhibition Of BTK Activity In Myeloma Cells Within a Supportive Microenvironment Promotes Their Growth But Suppresses Metastasis  Presenter: Rakesh Bam
  • The Antimalarial Agent Artesunate Exerts Its Antimyeloma Activity By Affecting The Mitochondria and The Reactive Oxygen Status Of The Myeloma Cells and Its Efficacy Depends On Intracellular Bivalent Iron Levels  Presenter: Xenofon Papanikolaou
  • Risk Of Myelodysplastic Syndrome (MDS) After Hematopoietic Progenitor Cell Collection Using Plerixafor   Presenter: Rashid Khan
  • Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients  Presenter:  Maurizio Zangari